Analyst Report: AXON
1. EXECUTIVE SUMMARY
Axon Enterprise fell 18.18% to $313.00 on Friday 6 November 2026, after a 9.81% drop on Thursday, on a third-quarter miss and a cut to full-year revenue guidance. According to Benzinga, Axon lowered 2026 revenue guidance to $3.61B to $3.63B (about 30% growth) from 32% to 34%, and blamed three federal Dedrone deployments worth about $130M that it no longer expects in 2026. Free cash flow guidance was also trimmed, and the company announced a $1.2B Skydio investment funded partly by a $1.15B raise. The Thursday decline, which came before the 4:15pm ET release, has no sourced explanation. Every analyst action in the brief kept a positive rating while cutting targets. The stock closed at a 52-week low and is down 44.45% year to date, with the market pricing in a reset of the growth story. Management and RBC describe the delayed deals as postponed, not lost.
2. THE CATALYST
Axon reported after the close on Thursday 5 November at 4:15pm ET (Yahoo Finance/StockStory). The quarter missed on both lines:
| Metric | Reported | Expected | Source |
|---|---|---|---|
| Revenue | $908.55M (+28% y/y) | $937.6M to $940.0M | Investing.com |
| Adjusted EPS | $1.72 | $1.88 to $1.91 | Investing.com |
| Q4 revenue guidance | $990M to $1.01B | about $1.06B | Benzinga |
The main driver was the full-year revenue guidance cut to $3.61B to $3.63B from a prior $3.67B to $3.725B (Benzinga). Axon attributed the reduction to three delayed federal Dedrone deployments totalling about $130M. On the call, management said the programs had been in its prior second-half expectations and represent about 500 basis points of growth (Benzinga transcript). Free cash flow guidance fell to $350M to $400M from $450M (Yahoo Finance/Zacks). Q4 adjusted EBITDA guidance is $245M to $250M (Investing.com).
Axon announced the same evening, per PR Newswire, a $1.2B investment in Skydio that lifts its fully diluted stake to 37% and makes it the exclusive U.S. public-safety distributor for Skydio. The investment is roughly 60% cash and 40% stock, and Axon raised $1.15B to fund it and add to the balance sheet (Benzinga transcript). Benzinga describes the raise as convertible securities. Reports of the Skydio valuation differ ($5.2B described as a total investment by Benzinga and as a pre-money valuation by MLQ), so the figure is unreliable.
| Session | Close | Change | Volume |
|---|---|---|---|
| 4 Nov | $424.18 | +1.83% | 851,300 |
| 5 Nov | $382.56 | -9.81% | 3,633,600 |
| 6 Nov | $313.00 | -18.18% | 5,225,400 |
The Thursday session ended before the release. Investing.com calls the move a pre-open slide, and no sourced item explains it. The brief records after-hours moves of -14%, -25% (Seeking Alpha) and about -16%, which differ from one another. Investing.com put the stock at $312.79, down 18.24%, at 12:51pm ET on Friday and called the decline company-specific.
3. COMPANY PROFILE
Axon provides public safety technology through two segments: Software and Services (cloud evidence management, Axon Evidence, Draft One, Axon Records, Fusus) and Connected Devices (Tasers, body cameras and related hardware). It is classified in Aerospace & Defense within Industrials. The market cap is $25.43bn, with a forward P/E of 30.7 and a trailing P/E of 129.9.
Third-quarter segment results from Benzinga and the shareholder letter:
- Software and Services revenue rose 43% to $437M.
- Connected Devices revenue rose 16% to $472M.
- Platform Solutions revenue rose 106% to $125M.
- Adjusted EBITDA rose 33% to $236M, a 25.9% margin (Yahoo Finance/Zacks).
- Operating cash flow fell to $20M from $60M (Yahoo Finance/Zacks).
- AI annual recurring revenue passed $100M, and AI bookings rose more than 50% (shareholder letter).
- Net revenue retention was 126% (Motley Fool transcript).
4. DEEP DIVE ANALYSIS
Do fundamentals justify the move? The brief supports a guidance reduction of about $60M to $95M at the midpoint of the ranges, set against a $130M slip that management attributes to the Dedrone deals. Underlying growth of 28% in the quarter and 43% in software remains strong. The cut matters most because Axon raised its outlook to 32% to 34% on 5 August (per a Levi & Korsinsky notice, a law-firm solicitation that is otherwise unverified) and reversed it three months later. Free cash flow guidance also fell, and operating cash flow dropped to $20M. RBC attributed margin and cash pressure to memory cost headwinds and deliberate inventory builds, and described the Dedrone slippage as procurement timing and election-cycle effects, with deals delayed rather than canceled.
The $1.15B raise, with a convertible component, adds a financing overhang to the same evening as the miss. In my inference, the combination of a guidance cut, a cash flow trim and new capital issuance explains why selling continued through Friday, although the brief does not attribute the move to the raise specifically.
Peers and sector. Over the same period, the S&P 500 rose 0.31%. Aerospace and defense peers were mixed: BA +0.52%, GE +2.70%, HWM +2.52%, RTX -1.22%, LMT -1.58%, NOC -0.05%. Coverage cited in the brief treats the fall as Axon-specific, and the researcher found no sector news that explains it.
Analyst reaction.
| Firm | Rating | Target change |
|---|---|---|
| Needham | Buy | $750 to $500 |
| Piper Sandler | Overweight | $561 to $540 |
| RBC Capital | Outperform | $735 to $615 |
| Raymond James | Outperform | $675 to $475 |
| Northland | Positive | $800 to $540 |
| Baird | Positive | $600 target |
The Northland and Baird entries come from a single source. A Craig-Hallum move to Hold appears only as a headline in MarketBeat, which the researcher did not open. The RBC note's date is unconfirmed, because its source says "Wednesday".
Comparable episodes. The brief identifies no earlier move caused by the same Dedrone or federal timing driver. The previous one-year low came on 10 April 2026 (247wallst), with no sourced link to this cause.
Bull case. The $130M of Dedrone deals is now expected in 2027, and their closing is the clearest upside trigger. Software growth, AI recurring revenue above $100M and retention of 126% remain intact. Piper Sandler expects pressure through year-end and a positive setup into 2027.
Bear case. Guidance has been raised and then cut within three months, which damages forecast credibility. Free cash flow is lower, operating cash flow has fallen, and the Skydio deal brings dilution and a large cash commitment. The unexplained 9.81% drop on Thursday leaves open whether information beyond the release was circulating.
5. TECHNICAL SNAPSHOT
The $313.00 close is the lowest in the daily table and sits just above the session low of $307.00, which is also the 52-week low, so no support level is visible in the data. The price is below the 50-day average of $441.53 and the 200-day average of $473.09, and 52.93% below the 52-week high of $665.07 set on 7 July. Resistance sits at the $382.56 close of 5 November. Friday's volume of 5,225,400 was 4.98x the 50-session average of 1,049,764, and Thursday's 3,633,600 was also elevated, which points to heavy repositioning over two sessions.
6. RISK FACTORS
- Further estimate cuts from analysts after the guidance reduction and the weaker Q4 outlook.
- Continued slippage in federal Dedrone timing into 2027, since the delay already moved from 2026.
- Dilution from the convertible securities and stock portion of the Skydio funding, plus execution risk on the investment.
- Margin and cash flow pressure from memory costs and inventory builds.
- Hardware growth: analysts are watching whether Taser growth returns above 10%.
- Possible legal action, since a law firm has already issued a solicitation notice.
- Unexplained Thursday weakness, which may signal information that has not yet surfaced.
Dated catalyst: the Q4 2026 report is tentatively scheduled for 2 March 2027 (Yahoo Finance/Investing.com explainer).
7. ACTIONABLE OUTLOOK
Short term (1-2 weeks): The stock closed at a 52-week low after two sessions of heavy volume, so volatility should stay high. Piper Sandler expects pressure through year-end. Additional target cuts and any detail on the convertible terms would weigh on the price, while stabilisation above the $307.00 session low would be the first sign that selling is easing.
Medium term (1-3 months): Without scheduled earnings before 2 March 2027, the stock is likely to trade on analyst revisions, evidence of federal procurement progress and information on Skydio. Confirmation that the Dedrone deals are moving toward closing would support recovery, and further slippage would extend the decline.
Long-term thesis: Software growth, AI revenue and retention figures in the brief are intact, and every cited analyst kept a positive rating. The change is a lower near-term growth path, weaker cash flow guidance and a larger capital commitment, which together reduce confidence in management's forecasts. Whether the thesis holds depends on the Dedrone deals closing in 2027. This is analysis only and not personal financial advice.